Last reviewed · How we verify
Depo-subQ Provera
Depo-subQ Provera is a Progestin; long-acting reversible contraceptive Small molecule drug developed by Teva Branded Pharmaceutical Products R&D, Inc.. It is currently FDA-approved for Contraception (prevention of pregnancy).
Depo-subQ Provera is a progestin that suppresses the luteinizing hormone surge, preventing ovulation and providing contraceptive efficacy.
Depo-subQ Provera is a small molecule that acts as a progesterone receptor agonist. It is used to treat conditions such as Polycystic Ovarian Syndrome and to induce ovulation, among other indications.
At a glance
| Generic name | Depo-subQ Provera |
|---|---|
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | Progestin; long-acting reversible contraceptive |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception; Women's Health |
| Phase | FDA-approved |
Mechanism of action
Medroxyprogesterone acetate (MPA) is a synthetic progestin that acts on the hypothalamic-pituitary-ovarian axis to inhibit gonadotropin-releasing hormone (GnRH) secretion and suppress the LH surge necessary for ovulation. By preventing ovulation and thickening cervical mucus, it provides long-acting reversible contraception. The subcutaneous formulation delivers sustained hormone levels over 12–13 weeks per injection.
Approved indications
- Contraception (prevention of pregnancy)
Common side effects
- Irregular bleeding or amenorrhea
- Headache
- Breast tenderness
- Weight gain
- Injection site reactions
- Mood changes or depression
Key clinical trials
- Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease (PHASE4)
- Counseling Among Gender Diverse Adolescents Who Use Depot Medroxyprogesterone (PHASE4)
- An Advanced Decision Support Tool for Personalized Medicine for IVF Using Modeling and Optimization for Provera (PHASE1, PHASE2)
- Estrogen Receptor Beta and Mood (PHASE2)
- Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer (PHASE4)
- Endometrial Biopsy in Progestin Contraceptive Users (EARLY_PHASE1)
- Postpartum Family Planning Program in Rwanda (NA)
- Quick Start of Highly Effective Contraception
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Depo-subQ Provera CI brief — competitive landscape report
- Depo-subQ Provera updates RSS · CI watch RSS
- Teva Branded Pharmaceutical Products R&D, Inc. portfolio CI
Frequently asked questions about Depo-subQ Provera
What is Depo-subQ Provera?
How does Depo-subQ Provera work?
What is Depo-subQ Provera used for?
Who makes Depo-subQ Provera?
What drug class is Depo-subQ Provera in?
What development phase is Depo-subQ Provera in?
What are the side effects of Depo-subQ Provera?
What does Depo-subQ Provera target?
Related
- Drug class: All Progestin; long-acting reversible contraceptive drugs
- Target: All drugs targeting Progesterone receptor
- Manufacturer: Teva Branded Pharmaceutical Products R&D, Inc. — full pipeline
- Therapeutic area: All drugs in Contraception; Women's Health
- Indication: Drugs for Contraception (prevention of pregnancy)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing